

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY DOCKET NO. P08898US00/BAS
		US APPL. NO. (If known, see 37CFR 1.5) 10/573,804
INTERNATIONAL APPLICATION NO. PCT/IB04/03146	INTERNATIONAL FILING DATE 28 September 2004	PRIORITY DATE CLAIMED 29 September 2003
TITLE OF INVENTION: IDENTIFICATION OF POLYMORPHISMS IN THE EPCR GENE ASSOCIATED WITH...		
APPLICANT(S) FOR DO/EO/US: AIACH		


Applicant herewith submits to the US Designated/Elected Office (DO/EO/US) the following items and other information:

- ☐ 1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☒ 2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 USC 371.
- ☐ 3. This is an express request to begin national examination procedures (35 USC 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
- ☐ 4. The US has been elected (Article 31).
- ☐ 5. A **copy** of the International Application as filed (35 U.S.C. 371 (c)(2))
 - ☐ a. is attached hereto (required only if not communicated by the International Bureau).
 - ☐ b. has been communicated by the International Bureau
 - ☐ c. is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ 6. An English **translation** of the International Application as filed (35 U.S.C. 371(c)(2)).
 - ☐ a. is attached hereto.
 - ☐ b. has been previously submitted under 35 U.S.C. 154(d)(4).
 - ☐ c. is not needed since the International Application is in English.
- ☐ 7. Amendments to the claims of the International Appln. under PCT Article 19 (35 USC 371 (c)(3))
 - ☐ a. are attached hereto (required only if not communicated by the International Bureau).
 - ☐ b. have been communicated by the International Bureau.
 - ☐ c. have not been made; however, the time limit for making such amendments has NOT expired.
 - ☐ d. have not been made and will not be made.
- ☐ 8. An English translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☒ 9. An oath or **declaration** of the inventor(s) (35 U.S.C. 371(c)(4)).
- ☐ 10. An English translation of the annexes to the Int'l Pre. Exam. Report under PCT Article 36 (35 USC 371(c)(5)).

Items 11. to 20. below concern document(s) or information included:

- ☒ 11. An **Information Disclosure Statement** under 37 C.F.R. 1.97 and 1.98.
- ☐ 12. An **Assignment** document for recording. A separate cover sheet in compliance with 37 CFR 3.28 & 3.31 is included.
- ☒ 13. A **preliminary amendment**.
- ☐ 14. An Application Data Sheet under 37 CFR 1.76.
- ☐ 15. A substitute specification.
- ☐ 16. A power of attorney and/or change of address letter.
- ☒ 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 & 37 CFR 1.821-825.
- ☐ 18. A second copy of the published international application under 35 USC 154(d)(4).
- ☐ 19. A second copy of the English translation of the international application under 35 USC 154(d)(4).
- 20. **Other** items or information:
 - ☐ Return Receipt Postcard.
 - ☒ A copy of the Notification of Missing Requirements under 35 U.S.C. 371.
 - ☒ In the event that a petition for extension of time is required to be submitted herewith, and in the event that a separate petition does not accompany this response, applicant hereby petitions under 37 CFR 1.136(a) for an extension of time of as many months as are required to render this submission timely. Any fee is authorized in 21(c).
 - ☐

COPY

U.S. APPLICATION NO. (If known) 10/573,804		INTERNATIONAL APPLICATION NO. PCT/IB04/03146		ATTORNEY DOCKET NO. P08898US00/BAS	
The following fees have been submitted:				CALCULATIONS	PTO USE ONLY
<input type="checkbox"/> 21. Basic national fee (37 CFR 1.492(a)) \$300				\$	
<input type="checkbox"/> 22. Examination fee (37 CFR 1.492(c))					
<input type="checkbox"/> Written Opinion or IPER by US indicates all claims satisfy PCT Art. 33(1-4) \$0				\$	
<input type="checkbox"/> All other situations \$200					
<input type="checkbox"/> 23. Search fee					
<input type="checkbox"/> Written Opinion or IPER by US indicates all claims satisfy PCT Art. 33(1-4) \$0				\$	
<input type="checkbox"/> Has been paid on the Int'l Appln. to the USPTO as ISA \$100					
<input type="checkbox"/> International Search Report prepared and provided to the Office \$400					
<input type="checkbox"/> All other situations \$500					
TOTAL OF 21, 22 AND 23				\$	
<input type="checkbox"/> SIZE FEE: sheets - 100 = ÷ 50 = [rounded up] × \$250 =				\$	
<input type="checkbox"/> Surcharge of \$130 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)) \$130				\$130	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	11 - 20 =	0	X \$50 =	\$0	
Independent Claims	3 - 03 =	0	X \$200 =	\$0	
<input type="checkbox"/> Multiple Dependent Claim(s) (if applicable)			+ \$360 =	\$	
TOTAL OF ABOVE CALCULATIONS =				\$130	
<input type="checkbox"/> Applicant claims small entity status - 37 CFR 1.27. Fees above reduced by ½.				\$	
SUBTOTAL =				\$130	
<input checked="" type="checkbox"/> Fee for Extension of Time				\$120	
TOTAL NATIONAL FEE =				\$	
<input type="checkbox"/> Fee for recording enclosed assignment (37 CFR 1.21(h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) \$40 per property				\$	
TOTAL FEES ENCLOSED =				\$250	
15/23/2007 MKAYPAGH 00000020 10573804 11 FC:1617 130.00 OP				Refunded	\$
				Charged	\$
<input checked="" type="checkbox"/> Payment of \$250 is made by attached Credit Card Payment Form (PTO-2038) <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required for this submission (except claims fees if the box below is checked) or credit any overpayment to Deposit Account No. 12-0555. <input type="checkbox"/> Do not charge any claim fees now - any additional claims fees will be paid with the Missing Requirements.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
POWER OF ATTORNEY & CORRESPONDENCE ADDRESS: CUSTOMER NO. 00881 Date: May 21, 2007			NAME: B. Aaron Schulman REG. NO.: 31,877 Signed (for by):  REG. NO.: 31,877		

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)	Application #	10/573,804
	Confirmation #	9377
	Filing Date	March 28, 2006
	First Inventor	AIACH
	Art Unit	
	Examiner	
	Docket #	P08898US00/BAS

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and fee under 37 CFR 1.17(a) are as follows.

COPY

☐ NOTE: Applicant claims small entity status.

No extension of time previously obtained.		
<u>Time Period</u>	<u>Large Entity Fee</u>	<u>Small Entity Fee</u>
<input checked="" type="checkbox"/> One month	<input checked="" type="checkbox"/> \$ 120	<input type="checkbox"/> \$ 60
<input type="checkbox"/> Two months	<input type="checkbox"/> \$ 450	<input type="checkbox"/> \$ 225
<input type="checkbox"/> Three months	<input type="checkbox"/> \$ 1020	<input type="checkbox"/> \$ 510
<input type="checkbox"/> Four months	<input type="checkbox"/> \$ 1590	<input type="checkbox"/> \$ 795
<input type="checkbox"/> Five months	<input type="checkbox"/> \$ 2160	<input type="checkbox"/> \$ 1080

☒ Payment by credit card. FORM PTO-2038 in the amount of \$250 is attached.

☒ The Director is authorized to charge any fee or additional fee due in connection herewith to Deposit Account No. 12-0555:

- (1) if no payment or an insufficient payment is enclosed and a fee is due in connection herewith; or
- (2) if a further fee and petition for extension of time are required at this time - and in this event, applicant hereby petitions under 37 CFR 1.136(a) for any further extension of time of as many months as are required to render this submission timely.

Date: May 21, 2007

05/23/2007 MKAYPAGH 00000020 10573804

02 FC:1251

120.00 PP

Signed By
Attorney of Record

Name: B. Aaron Schulman
Registration No.: 31,877

STITES & HARBISON PLLC ♦ 1199 North Fairfax St. ♦ Suite 900 ♦ Alexandria, VA 22314
TEL: 703-739-4900 ♦ FAX: 703-739-9577 ♦ CUSTOMER NO. 00881

<p style="text-align: center;">PRELIMINARY AMENDMENT</p>	Application #	10/573,804
	Confirmation #	9377
	Filing Date	03/28/06
	First Inventor	AIACH
	Art Unit	
	Examiner	
	Docket #	P08898US00/BAS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

 COPY

S I R:

Prior to examination

A) please consider the responsive **Remarks** and **Statement** provided herewith in

Attachment A; and


B) please amend the above identified application as follows:

- After page 29, please insert the **attached sequence listing** and substitute this listing for the one originally filed.
- A **Computer Readable Form** of the sequence listing is also provided.
- **Amendments to the Claims** are reflected in the listing of the claims provided herewith in **Attachment B**.

In view of the amendments made and the remarks provided, it is submitted that the present application is now in condition for examination and allowance.

Respectfully submitted,

Date: May 21, 2007


By: B. Aaron Schulman
Registration No.: 31,877

STITES & HARBISON PLC ♦ 1199 North Fairfax St. ♦ Suite 900 ♦ Alexandria, VA 22314
TEL: 703-739-4900 ♦ FAX: 703-739-9577 ♦ CUSTOMER No. 000881

ATTACHMENT A

REMARKS

By the present amendment, a sequence listing and diskette in suitable US form are now provided. Applicants state as follows:

STATEMENT

Applicants state in accordance with 37 C.F.R. § 1.821(f) that the content of the enclosed paper sequence listing and computer readable form are the same, and that in accordance with 37 C.F.R. § 1.821(g), the enclosed submission contains no new matter.

Applicants submit that this application is now in compliance with sequence listing requirements. The claims have also been amended to eliminate multiple dependencies.

Accordingly, Applicants submit that the present application is now in condition for examination and allowance.

END OF REMARKS

 **COPY**

ATTACHMENT B
Amendments to the Claims

A large, stylized, outlined 'COPY' stamp is located in the top right corner of the page.

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Original) An *in vitro* method for determining the risk of developing thrombosis in a subject, which method comprises identifying polymorphisms of EPCR gene on at least one of positions 1651, 3610, 4216, and 6936 (SEQ 10 NO:1), wherein the presence of G at position 1651, C at position 3610, A at position 4216, or G at position 6936 is indicative of a higher risk to develop thrombosis in comparison with a control subject that does not show the same polymorphisms.

2. (Original) An *in vitro* method according to claim 1, which method comprises identifying polymorphisms of EPCR gene at positions 1651, 3610, 4216, 6936, 3787, 3877, 4868, 5233, 5760, 6333, 7014, 7968, 7999 of SEQ 10 NO: 1, wherein the simultaneous presence of :

- G at position 1651
- C at position 3610
- A at position 4216
- G at position 6936
- C at position 3787
- G at position 3877
- T at position 4868
- G at position 5233
- T at position 5760

- T at position 6333
- G at position 7014
- A at position 7968
- G at position 7999

A large, stylized, outlined 'COPY' stamp is positioned in the upper right area of the page.

are designated A3 haplotype and, when present on at least one allele, are indicative of a higher risk to develop thrombosis in comparison with a control subject without any A3 allele.

3. (Currently Amended) The method according to claim 1 ~~or 2~~, wherein said thrombosis is a venous thrombosis.

4. (Currently Amended) The method according to ~~any of claims 1 to 3~~, wherein the analysis is undertaken on genomic DNA that is extracted from a biological sample of the subject.

5. (Currently Amended) The method according to ~~any of claims 1 to 4~~, wherein the analysis comprises a step of amplification of the genomic DNA.

6. (Currently Amended) The method according to ~~any of claims 1 to 5~~, wherein the polymorphisms of the EPCR gene are identified by sequencing.

7. (Currently Amended) The method according to ~~any of claims 1 to 6~~, wherein at least one of the polymorphisms of the EPCR gene is identified by RFLP analysis.

8. (Original) The method according to claim 7, comprising identifying the polymorphism of EPCR gene on position 6936, by creating a restriction site for endonuclease PstI by amplification of the EPCR gene with mutagenic primers, when the amplified fragment contains an A at position 6936, so that when the amplified fragment containing a G, it remains undigested.
9. (Original) An isolated nucleic acid encoding the EPCR receptor, that comprises SEQ ID NO:2.
10. (Currently Amended) A kit suitable for the methods according to ~~any of~~ claims 1 to 6, which kit comprises a pair of nucleotide primers specific for amplifying all or part of the EPCR gene comprising at least one of positions 1651,3610,4216 of SEQ ID NO:1.
11. (Original) A method for genotyping the EPCR gene, which method comprises identifying the polymorphism of the EPCR gene at position 4216 (SEQ ID NO: 1), wherein the presence of C at position 4216 shows the Ai haplotype, the presence of G at position 4216 shows the A2 haplotype, and the presence of A shows the A3 haplotype.

SEQUENCE LISTING

COPY

<110> AIACH et al.

<120> Identification of polymorphisms in the EPCR gene
associated with thrombotic risk

<130> P08899US00/BAS

<140> 10/573,804

<141> 2006-03-28

<160> 18

<170> PatentIn Ver. 2.1

<210> 1

<211> 8167

<212> DNA

<213> Homo sapiens

<400> 1

```
aaatgaaata tttcaggctg tgcacagtgg ctcaggcttg taatcccagc atgttgggag 60
gctgaagtgg gcgcatcacc tgaggtcagg agtttgagac caacctggcc aacatgggtga 120
aatcccatct ctactaaaaa tacaaaaatt agccagggtg ggtggcagggt gactgtaatc 180
ccagctactt gggaggctga ggcaggagaa tcgcttgaat ctgggagggtg gaggttgagc 240
tgagccgaga tcacgccact gcatacagca agactccatc tcaaaaaaaaa gaaaaaaaaa 300
aagaaaaaag aaatgtttca taatttttaa taaaaggcaa gacaatataa attggtagtt 360
atttaagtca ttctactttt cctgaggccc agtgcaggaa aacaaagttc ctatccttgt 420
tccaaactaga ccattttgat aagctgcaaa aagaaaagac tttgatgcta tttcttagcc 480
agtttgcaac agctgagagg tgagcatgga agctcttgca tatattcagt tcagagaatg 540
ggtgcttagt ttatgtccag agtttgtccc agatttcact atgacgtcag ctctccgggg 600
agaagtatat aaaataaaaa gttaaaatcc ctctcagtc tttacccaat cctattcccc 660
agaggtaatc tctattgaca gtacccctcc agatattttc cctatgtata taaaaatata 720
cagatacaca ctgaaagtta attttggcca ggtgcagtgg ctctgccta taccagagga 780
ttgcttgagt gcaggagttc aagaccagcc tgggcaacat agcgagacca catctctagt 840
aaaaataaaa aaaaaatagc taggcgtggg ggcacagtgg cacgtacctt tagtctcagc 900
tactcgggtg gttgagggtg gagaatcact tgagcccggt aggtcaagcc tacaattagc 960
tgtgattgct tctactgact atagcctggg caacagagct agaccctgtc tcaaaaaaat 1020
aataataaat tttatatata tatatgagga tgaaattaca tatgtattat ttgaacagaa 1080
gtgaaatctt ttcttttttt ttttcagaca gaatcttgcc gcatgaccca ggctagaatg 1140
cagtgggtgtg atctcggccc tctgcaacct ccacctccca ggttcaagcg attctcatgc 1200
ctcgggtctcc caagtagctg ggattacagg catgcaccac catgccagc taatttttgt 1260
atttttcgta gagacgttcg ccatattggc caggctgggt tcaaaactct ggcctcaagt 1320
gatctgcccc cctcggcctc ccaaagtgcg agcagcatgc tcggaggagt gactttaaag 1380
cttttctact tgcttcctag agtaagggtg gcattttaca ctgctatcca aaactcatca 1440
tagaaacata cacacacaaa accaaagcac acatatacaa ctgagcaa atttcatgac 1500
ataacacttt ctcttactaa ggggtgacgc ctgaaatttt gtattctgtc ctatttcatt 1560
ttttaaaaaat ggtaaccatg acctgctaaa ttgatttcat tgtccactaa taaattatga 1620
cctcagtttc aaaaagattg ctttaggtaa ccaatcatct tctgagattt atacagattg 1680
ctcataattc tctcctattt tttaaaaaca tgctgcagtg aactgcttta cactcatttt 1740
atgactactt ctgagacc aa gatcccgat tatgtaattg ttatttactt aaaattctgg 1800
taaaatgtag ccattatact ggaaaactaa attttaatct tggatctgtc accaccatga 1860
tatataaact ttgggcaagt ccctgcacct ctctggacct caatctcccc atcagcaacc 1920
tgctgatcct actcccagga gtgtgctcta agttgaaagt agatgcccc cccctgagt 1980
cagcgccggc agacttctc accaagccct tctccccctt ttccgctccc tgttctgtgt 2040
tcttaggaag cagcccaagg agaagggaaa aggcagggtc gggcaggagg gagcaatgaa 2100
gggcggggca gagggagggc aggaggagg cgggccccct agtaggaaat gagacacagt 2160
agaaataaca ctttataagc ctcttcctcc tcccatctcc tggcctcctt ccctcctcct 2220
ctgcccagac tccgcccctc ccagacgggc ctcacttctc ttttccttag actgcagcca 2280
gcggagcccc cagccggccc gagccaggaa cccaggctcg gagcctcaac ttcaggatgt 2340
```


tgacaacatt	gctgccgata	ctgctgctgt	ctggctgggc	cttttgtagc	caagacgcct	2400
cagatggtga	gtcgggggca	catctcctgc	ctcaggatgg	ttctggagaa	tctcagtcta	2460
tctgggcaca	tggcaagacc	acaggagagc	ttatctcaca	gcatctgtgt	ctgcagctgg	2520
ctagatctct	ctacagggca	ggcagagtct	tggggactgg	ttcgtgtccc	aaagccaagg	2580
tgagttagta	cattttaagcc	cctgaaaagg	gggagatgaa	agaggctagg	ggaaacagga	2640
tgactggaaa	catgagaaaag	aaaccagcag	agagggtagg	agaatcagcc	ccaggggagag	2700
gggagaaaagg	ggaactgagg	gtgatggtag	ataggggtac	atctagggga	gacgggaaga	2760
ggctcagaag	agaagagaaa	tggaggggaat	gggaagaccc	tgggaaaact	gatggaagaa	2820
gtgggggaag	agtggggcag	agagaggtta	gggagggcta	gggaaaatgg	aaggagactg	2880
gtgcgagctg	gtggaactgg	ggagaaaagag	atgctgtgcc	taatagaact	tatgggcat	2940
caggctactg	aagtggccct	gtttaagcag	aaaagggagt	tattaccctc	cattataatt	3000
gcacaggggc	ctcctttccc	ctctctcaca	atccccgtaa	cttcagtctc	cccctcagag	3060
aggcagcaaa	taataaccag	tattcaatga	gtgctcacta	tgggtaatac	atgtattgac	3120
ccattttaact	tgcacaaaacc	cctaaagggtg	ggtaatatta	ttactatctc	cattttatga	3180
ggaggaaaact	gggtcacaga	gtagttaagg	accatgtcta	gggttatcca	taaataatact	3240
tattcacatc	tgcagataca	aagcacaact	tctcaaatgc	aaacacagac	aggaccact	3300
cacacacaca	gatttacaac	cccgactca	tccaaatgtg	ctctgggcat	caactctgtg	3360
ccagcctctt	ttctgggtgt	aggaagcaga	gattaccaag	catggttcca	tagcctagag	3420
gagtcacagt	tggcctgtgt	gtgtttggag	acagccaggt	agtatcccg	gagatacaca	3480
ctaataatat	gtggtctggg	atcactgaaa	cagacacact	gtgtctctgt	gggcatcaga	3540
aaaaaatttc	caagaagagg	gcaactgagc	tgggtctttt	tttctttgct	tttctttctt	3600
ttttcttttt	tttttttttt	tttttttttg	agatggagtc	ttgtgctgtc	accagggtg	3660
gaatgcagt	gcacaatttc	agctaactgt	aacctccaac	tcccaggttc	aggcgattct	3720
cctgcctcag	cctcctgagt	agctgggact	acaggcatgt	accaccacgc	ctggctaata	3780
tttgtacttt	tagtacagat	ggggtttcgc	catgttggcc	aggctggtct	tgaatccctg	3840
acctcagagt	atccgcccgc	ctcggcctcc	caaagtgtg	ggattacagg	catgagccac	3900
cgcgccagtg	ctctgagctg	ggtctttaat	catgaataaa	cttcgccagg	cagaaaaagg	3960
gaggcagagc	aatcctgaca	tgctattcat	gtgtcagcca	aaggcagcat	gaggaatccc	4020
aactagtttg	atatataagc	agcgggaagc	ggccagaaaa	ggcagcaggg	gccagggtctc	4080
tagcagcctt	gaatgccagg	ctaaagactc	tggacttgat	cctgtgggga	ggcagtgtag	4140
cagaatggct	gagtgctgga	cttgactgcc	tacgtgcaaa	ccttggtctt	gctacactat	4200
ctctgtctca	gtttcgcatg	tagactgggg	ttaataatag	tagctattgc	attaagccac	4260
tggggaaaagg	cacaaagata	ataatgtatg	taaagcccat	tgcccagggt	ataataagca	4320
ctgaatcgac	attggctatg	attatttttg	attaatgaag	gggagggggt	tatggcactg	4380
gaagatttta	agtaggaaaa	ggacatgac	tcatccctgg	gtcaggtgga	ggtcgggaata	4440
gagacggggg	agatgaagta	gaaagttact	accccagtct	agatgagacg	gatgaatcct	4500
gaatcagggc	agtggaagag	gagatggaga	acaggcgatg	gaattggaat	tttattcagg	4560
tcaggatttg	ttaaccattt	gttccgttgg	ttaacaggaa	acgggggggag	ggagagccga	4620
gggtgaaaaa	ggaggcagaa	aggagtgtct	cttccactgc	aggcctcagt	ttcctcatct	4680
gtaaaacgga	gataataatc	cctgtcctgt	cctcctggca	gagttactgt	cagcgtcaaa	4740
cgggagaagc	ggtgggaggg	cacattatag	tttatgaagg	gtcgagaagg	cgggaggcca	4800
gcctcgagg	agggggttat	tatcttcgcg	tgcccgcgcg	ccccctccac	gccggcccag	4860
gctgaagttg	actctgcccg	caggcctcca	aagacttcat	atgtccaga	tctcctactt	4920
ccgcgacccc	tatcacgtgt	ggtaccagg	cacacgcgtc	ctggggggac	acctaacgca	4980
cgtgctggaa	ggcccagaca	ccaacaccac	gatcattcag	ctgcagccct	tgcaggagcc	5040
cgagagctgg	gcgcgcacgc	agagtggcct	gcagtcctac	ctgctccagt	tccacggcct	5100
cgtgcgcctg	gtgcaccagg	agcggacctt	ggcctgtgag	taggcgcgca	gcggggggcg	5160
ggtctgggcg	gggctagtgg	gggcggggcc	tggcggtgg	gggcggggcc	tggcggtagg	5220
aggcgggctg	gggcttgag	ggaccgggca	gccactggag	ctcggtggcg	cctgggcctt	5280
tgaagattgc	tgggtggggg	ctggagagag	gcagttgtcc	ccgctaagaa	agccccgact	5340
cgggcgggtcg	tctgtctggc	ataacctctt	gggatagacc	ctgttggaag	gccctgacac	5400
cgtgacgtcg	aaggtcccca	gaaaactcct	cacccctcgc	ctcacagtcc	tccaactcct	5460
tttcttcata	gatctccgtc	cttcccttcc	cagacccccc	agcacttcac	ccccaccct	5520
ccagccactt	ctcatacaag	ctgatgactt	cgctcttagc	tccactcatg	accggaactc	5580
ttcccccaaa	gaccccaagt	tcttctctca	aagccccact	ccttccccgt	cacaacccta	5640
actccttctt	ctcaaagacc	ccaatttctt	ttctcaaagc	accaagcacc	actccgtccc	5700
ccttccccca	ccatcatggc	ctttaattcc	ttctctcct	agtccccac	cccacccct	5760
tttttttttt	tttttttttt	tttttttgag	acggagtctt	gctctgtcgt	ccaggctgga	5820
gtgcagtggc	gcgatctcgg	ctcactgcaa	cttccgcctc	ccgggttcaa	gcgattctcc	5880
tgccctcagcc	tcceaagcag	ctgggactac	aggcaccgcg	caccacgccc	ggctaatttt	5940
ttgtattttt	agtagagacg	gggtttcgcg	atgttggcca	ggctggtctc	gaactcctga	6000

 COP

COPY

cctcaggcga	tccacaagcc	tggcctccca	aagtgtctgg	attacaggcg	tgagctgccg	6060
cccctgcccc	agcctcacc	cctgtttttt	ttttctatta	cagttgaaca	aggcctgaca	6120
attccctttt	ttcatcacag	tccttgcccc	cttctttctt	agcctctaac	aggctaacc	6180
caaacccttc	ctcacagccc	caggcocttc	tccccatagt	tccttgacct	agactccctt	6240
ctcctcacag	cactgactct	tgcctttctc	tgttcttttc	cccttggtgg	gcctcgcccc	6300
acacctggca	ccctctctgc	acagtccctt	gatectgact	gtctatccac	agttcctctg	6360
accatccgct	gcttcctggg	ctgtgagctg	cctcccgagg	gctctagagc	ccatgtcttc	6420
ttcgaagtgg	ctgtgaatgg	gagctccttt	gtgagtttcc	ggccggagag	agccttggtg	6480
caggcagaca	cccaggtcac	ctccggagtg	gtcaccttca	ccctgcagca	gctcaatgcc	6540
tacaaccgca	ctcggtatga	actgcgggaa	ttcctggagg	acacctgtgt	gcagtatgtg	6600
cagaaacata	tttcgcggga	aaacacgaaa	ggtatgatgg	gacggggccc	aggcctgcaa	6660
gctggggaga	gggcggttc	cagacaaatg	gatggacctg	aaggatggat	gcctagagca	6720
acaagaggcc	cacagctggg	ggtttgggac	agaacacacg	cagcttcagt	cagttggtaa	6780
acgggtccct	ttcctctggg	gcagaaacgc	tttggggttt	gactcaaadc	atggactcct	6840
tgggggccta	ttcttcgggc	taactctttg	catgttctgc	agggagccaa	acaagccgct	6900
cctacacttc	gctggtcctg	ggcgtcctgg	tgggcagttt	catcattgct	ggtgtggctg	6960
taggcactct	cctgtgcaca	ggtggacggc	gatgttaatt	actctccagc	cccgtagaaa	7020
ggggcctggat	tgtatggagg	tggcaaggga	aagtttcagc	tcactgtgaa	gccagactcc	7080
ccaactgaaa	caccagaagg	tttggagtga	cagctccttt	cttctcccac	atctgcccac	7140
tgaagatttg	agggagggga	gatggagagg	agaggtggac	aaagtacttg	gtttgctaag	7200
aacctaagaa	cgtgtatgct	ttgctgaatt	agtctgataa	gtgaatgttt	atctatcttt	7260
gtggaaaaca	gataatggag	ttggggcagg	aagcctatgg	cccatcctcc	aaagacagac	7320
agaatcacct	gaggcggtca	aaagatatata	ccaaataaac	aagtcatcca	caatcaaaat	7380
acaacattca	atacttccag	gtgtgtcaga	cttgggatgg	gacgctgata	taatagggta	7440
gaaagaagta	acacgaagaa	gtggtggaaa	tgtaaaatcc	aagtcatatg	gcagtgatca	7500
attattaatc	aattaataat	attaataaat	ttcttatatt	taaggcattg	ttatctcctc	7560
cactttgcaa	aattttctgga	aaagtaacct	ataccatttt	cttctgcttc	cttattttctc	7620
actcattctt	tttttttttt	tttttttttt	ttgagacaga	gtcttgctct	gttgccctagg	7680
ctggagtga	atggtgtgat	ctcagctcac	tgcaacctct	gcctcccggg	tcaagcaatt	7740
ctcctgcctc	agcctcccaa	gcagctggga	ttacagatgc	atgccaccac	accagctaa	7800
tttttgattt	tttagtagag	atgggggttt	accacgttgg	ccatcctgac	ctcgtgatcc	7860
gcctacctcg	gcctccccaa	gtgctgggat	tagacgtgag	ccactgcgcc	tggtcttctc	7920
actcattctt	agaccagtg	caatctgact	tctctataaa	ctactctaag	atcaccagta	7980
acctctaatt	gtcaaaccgt	cacctacat	ggtatctgca	aatttgcgga	ctagaactct	8040
ctttttgco	taacttctga	gataccatac	ttcaattttt	aaaactgttc	tgtctacttt	8100
ttttcaatcc	ctttgactat	gtcatctttac	acgattcacc	ctggaaatgc	tggtcttcctt	8160
agaattc						8167

<210> 2

<211> 8167

<212> DNA

<213> Homo sapiens

<400> 2

aaatgaaata	tttcaggctg	tgcacagtgg	ctcaggcttg	taatcccagc	atgttggggag	60
gctgaagtgg	gcgatcacc	tgaggtcagg	agtttgagac	caacctggcc	aacatgggtga	120
aatcccatct	ctactaaaaa	tacaaaaatt	agccagggtg	ggtggcagg	gactgtaatc	180
ccagctactt	gggaggctga	ggcaggagaa	tcgcttgaat	ctgggagggt	gaggttgtag	240
tgagccgaga	tcacgccact	gcatacagca	agactccatc	tcaaaaaaaa	gaaaaaaaaa	300
aagaaaaaag	aaatgtttca	taatttttaa	taaaaggcaa	gacaatataa	attggtagtt	360
atttaagtca	ttctactttt	cctgaggccc	agtgaggaa	aacaaagtgc	ctatccttgt	420
tccaactaga	ccattttgat	aagctgcaaa	aagaaaagac	tttgatgcta	tttcttagcc	480
agtttgcaac	agctgagagg	tgagcatgga	agctcttgca	tatattcagt	tcagagaatg	540
ggtgcttagt	ttatgtccag	agtttgtccc	agatttcact	atgacgtcag	ctctccgggg	600
agaagtatat	aaaataaaaa	gttaaaatcc	ctctcagtc	tttaccat	cctattcccc	660
agaggtaatc	tctattgaca	gtacccctcc	agatattttc	cctatgtata	tacaaatata	720
cagatacaca	ctgaaagtta	attttggcca	ggtgcagtgg	ctcctgccta	taccagagga	780
ttgcttgagt	gcaggagttc	aagaccagcc	tgggcaacat	agcgagacca	catctctagt	840
aaaaataaaa	aaaaaatagc	taggcgtggg	ggcacagtgg	cacgtacctt	tagtctcagc	900
tactcgggtg	ggttaggtgg	gagaatcact	tgagcccggg	aggtcaagcc	tacaattagc	960

COPY

tgtgattgct	tcaactgcact	atagcctggg	caacagagct	agaccctgtc	tcaaaaaaat	1020
aataataaat	tttatatata	tatatgagga	tgaaattaca	tatgtattat	ttgaacagaa	1080
gtgaaatcct	ttcttttttt	ttttcagaca	gaatcctgcc	gcatgacca	ggctagaatg	1140
cagtgggtgtg	atctcggccc	tctgcaacct	ccacctccca	ggttcaagcg	attctcatgc	1200
ctcgggtctcc	caagtagctg	ggattacagg	catgcaccac	catgcccagc	taatttttgt	1260
attttttcgta	gagacgttcg	ccatattggc	caggctgggc	tcaaactcct	ggcctcaagt	1320
gatctgcccc	cctcggcctc	ccaaagtgcc	agcagcatgc	tcgaggaggt	gacttttaag	1380
ctttttctact	tgcttcttag	agtaaggagc	gcatttttaca	ctgctatcca	aaactcatca	1440
tagaaacata	cacacacaaa	accaaagcac	acatatataa	ctgagcaaat	atttcatgac	1500
ataaacacttt	ctcttactaa	gggtgacgcg	ctgaaatttt	gtattctgtc	ctatttcatt	1560
ttttaaaaaat	ggtaaccatg	acctgctaaa	ttgatttcat	tgtccactaa	taaattatga	1620
cctcagtttc	aaaaagattg	ctttaggtaa	gcaatcatct	tctgagattt	atacagattg	1680
ctcataattc	tctcctattt	tttaaaaaaca	tgctgcagtg	aactgcttta	cactcatttt	1740
atgactactt	ctgagaccaa	gatcccggat	tatgtaattg	ttattttact	aaaattctgg	1800
taaaatgtag	ccattatact	ggaaaactaa	attttaatct	tggatctgtc	accaccatga	1860
tatataaact	ttgggcaagt	ccctgcacct	ctctggacct	caatctcccc	atcagcaacc	1920
tgtgtatcct	actcccagga	gtgtgctcta	agtgtgaaagt	agatgcccc	ccccctgagt	1980
cagcgccggc	aggacttctc	accaagccct	tctccccctt	ttccgctccc	tgttccctgg	2040
tcctaggaag	cagcccaagg	agaaggga	aggcaggctc	gggcaggagg	gagcaatgaa	2100
ggcgggggca	gagggagggc	aggagggagg	ccggccccct	agtaggaaat	gagacacagt	2160
agaaataaca	ctttataagc	ctcttctctc	tcccatctcc	tggcctcctt	ccatcctcct	2220
ctgcccagac	tccgcccctc	ccagacgggc	ctcacttctc	ttttccctag	actgcagcca	2280
gcgaggcccg	cagccggccc	gagccaggaa	cccaggtcog	gagcctcaac	ttcaggatgt	2340
tgacaacatt	gctgccgata	ctgctgctgt	ctggctgggc	cttttgtagc	caagacgcct	2400
cagatggtga	gtcgggggca	catctcctgc	ctcaggatgg	ttctggagaa	tctcagtcta	2460
tctgggcaca	tggcaagacc	acaggagagc	ttatctcaca	gcactctgtg	ctgcagctgg	2520
ctagatctct	ctacagggca	ggcagagtct	tggggactgg	ttcgtgtccc	aaagccaagg	2580
tgagttagta	catttaagcc	cctgaaaagg	gggaatgaa	agaggctagg	ggaaacagga	2640
tgactggaaa	catgagaaag	aaaccagcag	agagggtagg	agaatcagcc	ccaggggagag	2700
gggagaaagg	ggaactgagg	gtgatggtag	ataggggtac	atctagggga	gacgggaaga	2760
ggctcagaag	agaagagaaa	tggaggggaat	gggaagacc	tgggaaaact	gatggaagaa	2820
gtgggggaag	agtggggcag	agagagggtta	ggggaggcta	gggaaaatgg	aaggagactg	2880
gtcgcagctg	gtggaactgg	ggagaaaagag	atgctgtgcc	taatagaact	tatgggcat	2940
caggctactg	aagtggccct	gtttaagcag	aaaagggagt	tattaccctc	cattataatt	3000
gcacaggggc	ctcctttccc	ctctctcaca	atccccgtaa	cttcagtctc	cccctcagag	3060
aggcagcaaa	taataaccag	tattcaatga	gtgctcacta	tggttaatat	atgtattgac	3120
ccattttaact	tgcacaaacc	cctaaagggtg	ggtaatatata	ttactatctc	cattttatga	3180
ggaggaaact	gggtcacaga	gtagttaagg	accatgtcta	gggttatcca	taaataatact	3240
tattcacatc	tgcagatata	aagcacaact	tctcaaatgc	aaacacagac	aggaccact	3300
cacacacaca	gattttacaac	cccggactca	tccaaatgtg	ctctgggcat	caactctgtg	3360
ccagcctctt	ttctgggtgt	aggaagcaga	gattaccaag	catggttcca	tagcctagag	3420
gagtccagtg	tggcctgtgt	gtgtttggag	acagccagggt	agtatcccgt	gagatacaca	3480
ctaataatatg	gtggtctggg	atcactgaaa	cagacacact	gtgtctctgt	gggcatcaga	3540
aaaaaaatttc	caagaagagg	gcaactgagc	tgggtctttt	tttcttttct	tttcttttct	3600
ttttcttttct	tttttttttt	tttttttttt	agatggagtc	ttgtgctgtc	accagggctg	3660
gaatgcagtg	gcacaatttc	agctaaactgt	aacctccaac	tcccagggtc	aggcgattct	3720
cctgcctcag	cctcctgagt	agctgggact	acaggcatgt	accaccacgc	ctggctaata	3780
tttgtagctt	tagtacagat	ggggtttcgc	catgttgcc	aggctggtct	tgaatccctg	3840
acctcaagtg	atccgcccgc	ctcggcctcc	caaagtgtctg	ggattacagc	catgagccac	3900
cgcgccaggt	ctctgagctg	ggtcttaaat	catgaataaa	cttcgccagc	cagaaaaagg	3960
gaggcagagc	aatcctgaca	tgctattcat	gtgtcagcca	aaggcagcat	gaggaatccc	4020
aactagtttg	atatataagc	agcgggaagc	ggcagaaaa	ggcagcagg	gccaggtctc	4080
tagcagcctt	gaatggcagg	ctaaagactc	tggacttgat	cctgtgggga	ggcagtgtag	4140
cagaatggct	gagtgtctga	cttgactgcc	tacgtgcaaa	ccttggtctc	gctacactat	4200
ctctgtctca	gtttcacatg	tagactgggg	ttaataatag	tagctattgc	attaagccac	4260
tggggaaagg	cacaaagata	ataatgtatg	taaagcccat	tgcccagggt	ataataagca	4320
ctgaatcgac	attggctatg	attatttttg	attaatgaag	gggagggggt	tatggcactg	4380
gaagattttta	agtaggaaaa	ggacatgatc	tcacccctgg	gtcagggtga	ggtcggaata	4440
gagaacgggg	agatgaagta	gaaagttact	accccagctc	agatgagacg	gatgaatcct	4500
gaatcagggc	agtggaaag	gagatggaga	acaggcgatg	gaattggaat	tttattcagg	4560
tcaggatttg	ttaaccattt	gttccgttgg	ttaacaggaa	acggggggag	ggagagccga	4620

COPY

gggtgaaaaa	ggaggcagaa	aggagtgtct	cttccactgc	aggcctcagt	ttcctcatct	4680
gtaaaacgga	gataataatc	cctgtcctgt	cctcctggca	gagttactgt	cagcgtcaaa	4740
cgggagaagc	ggtgggaggg	cacattatag	tttatgaagg	gtcgagaagg	cgggaggcca	4800
gcctcgaggt	agggggttat	tatcttccgc	tgcccgccgc	cccctcccac	gccgggccag	4860
gctgaagttg	actctgcccg	caggcctcca	aagacttcat	atgctccaga	tctcctactt	4920
ccgcgacccc	tatcacgtgt	ggtaccaggg	caacgcgtcg	ctggggggac	acctaacgca	4980
cgtgctggaa	ggcccagaca	ccaacaccac	gatcattcag	ctgcagccct	tgcaggagcc	5040
cgagagctgg	gcgcgcacgc	agagtggcct	gcagtccctac	ctgctccagt	tccacggcct	5100
cgtgcgcctg	gtgcaccagg	agcggacctt	ggcctgtgag	taggcgcgca	gcggggggcg	5160
ggtctgggcg	gggctagtgg	ggggggggcc	tggcggtggg	ggcgggggcc	tggcggtagg	5220
aggcggtctg	gggcttgag	ggaccgggca	gccactggag	ctcggtggcg	cctgggcctt	5280
tgaagattgc	tgggtggggg	ctggagagag	gcagttgtcc	ccgctaagaa	agccccgact	5340
cgggcggtcg	tcctgctggc	ataacctctt	gggatagacc	ctggtggaag	gccctgacac	5400
cgtgacgtcg	aaggtcccca	gaaaactcct	cacccctcgc	ctcacagtcc	tccaaactcct	5460
tttcttcata	gatctccgtc	cttcccttcc	cacagccccc	agcacttcac	ccccaccctt	5520
ccagccactt	ctcatacaag	ctgatgactt	cgctcttagc	tccactcatg	acccgaacte	5580
ttccccaaaa	gaccccaagt	tcttctctca	aagccccact	ccttcccctg	cacaacccta	5640
actccttctt	ctcaaagacc	ccaatttctt	ttctcaaagc	accaagcacc	actccgtccc	5700
ccttccccca	ccatcatggc	ctttaattcc	tttctctcct	agtcccccc	cccacccctt	5760
tttttttttt	tttttttttt	tttttttgag	acggagtctt	gctctgtcgt	ccaggctgga	5820
gtgcagtggc	gcgatctcgg	ctcactgcaa	cttccgcctc	ccgggttcaa	gcgattctcc	5880
tgccctagcc	tcccaagcag	ctgggactac	aggcaccgcg	caccacgccc	ggctaatttt	5940
ttgtattttt	agtagagacg	gggtttcgcc	atggtggcca	ggctggtctc	gaactcctga	6000
cctcaggcga	tccacaagcc	tggcctccca	aagtgtctgg	attacaggcg	tgagctgccg	6060
cccctgcccc	agcctcaccc	cctgtttttt	ttttctatta	cagttgaaca	aggcctgaca	6120
attccctttt	ttcatcacag	tccctggccc	cttcttcttt	agcctctaac	aggctaacc	6180
caaacccttc	ctcacagccc	caggcccttc	tccccatagt	tccctgacct	agactccctt	6240
ctcctcacag	cactgactct	tgccttctca	tgttcttttc	cccttggtgg	gcctcgcccc	6300
acacctggca	ccctctctgc	acagtccctt	gatcctgact	gtctatccac	agttcctctg	6360
accatccgct	gcttctctgg	ctgtgagctg	cctcccaggg	gctctagagc	ccatgtcttc	6420
ttcgaagtgg	ctgtgaatgg	gagctccttt	gtgagtttcc	ggccggagag	agccttggtg	6480
caggcagaca	cccaggtcac	ctccggagtg	gtcaccttca	ccctgcagca	gctcaatgcc	6540
tacaaccgca	ctcggtatga	actgcgggaa	ttcctggagg	acacctgtgt	gcagtatgtg	6600
cagaaacata	tttccgcgga	aaacacgaaa	ggtatgatgg	gacggggccc	aggcctgcaa	6660
gctggggaga	ggcggggttc	cagacaaatg	gatggacctg	aaggatggat	gcctagagca	6720
acaagaggcc	cacagctggg	ggtttgggac	agaacacacg	cagcttcagt	cagttggtaa	6780
acgggtccct	ttcctctggg	gcagaaacgc	tttggggttt	gactcaaatc	atggactcct	6840
tgggggccta	ttcttcgggc	taactctttg	catgttctgc	aggagagcaa	acaagccgct	6900
cctacacttc	gctggtcctg	ggcgctcctg	tggcggtttt	catcattgct	gggtgtggctg	6960
taggcattct	cctgtgcaca	ggtggacggc	gatgttaatt	actctccagc	cccgtcagaa	7020
ggggctggat	tgatggaggc	tggcaaggga	aagtttcagc	tcactgtgaa	gccagactcc	7080
ccaactgaaa	caccagaagg	tttggagtga	cagctccttt	cttctccccc	atctgcccac	7140
tgaagatttg	agggaggggg	gatggagagg	agagggtggc	aaagtacttg	gtttgctaag	7200
aacctaaaga	cgtgtatgct	ttgctgaatt	agtctgataa	gtgaatgttt	atctatcttt	7260
gtggaaaaca	gataatggag	ttggggcagg	aagcctatgg	cccatcctcc	aaagacagac	7320
agaatcacct	gaggcggttc	aaagatataa	ccaaataaac	aagtcatcca	caatcaaaat	7380
acaacattca	atacttccag	gtgtgtcaga	cttgggatgg	gacgctgata	taatagggta	7440
gaaagaagta	acacgaagaa	gtggtggaaa	tgtaaaatcc	aagtcatatg	gcagtgatca	7500
attattaatc	aattaataat	attaataaat	ttcttatatt	taaggcattg	ttatctcctc	7560
cactttgcaa	aatttctgga	aaagtaacct	atacccattt	cttctgcttc	cttatttctc	7620
actcattctt	tttttttttt	tttttttttt	ttgagacaga	gtcttgctct	gttgccctagg	7680
ctggagtgca	atggtgtgat	ctcagctcac	tgcacacctc	gcctcccggg	tcaagcaatt	7740
ctcctgcctc	agcctcccaa	gcagctggga	ttacagatgc	atgccaccac	accagctaa	7800
tttttgtatt	tttagtagag	atggggtttc	accacgttgg	ccatcctgac	ctcgtgatcc	7860
gcctacctcg	gcctcccca	gtgctgggat	tagacgtgag	ccactgcgcc	tggctcttct	7920
actcattctt	agaccagtg	caatctgact	tctctataaa	ctactctaag	atcaccagta	7980
acctctaatt	gtcaaaccgt	caccctacat	ggtatctgca	aatttgcgga	ctagaactct	8040
ctttttgcct	taacttctga	gataccatac	ttcaattttt	aaaactgttc	tgtctacttt	8100
ttttcaatcc	ctttgactat	gtcatcttac	acgattcacc	ctggaaatgc	tggcttctct	8160
agaatttc						8177

COPY

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 3
gctgaagtgg gcggatcacc

20

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 4
tctagcctgg gtcatgcggc

20

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 5
tcttgccgca tgacccaggc

20

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 6
ggaaggaggc caggagatgg

20

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 7
ctcttactaa ggggtgacgcg

20

COPY

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 8
tctgatgccc cacgagacac 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 9
tctctacagg gcaggcagag 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 10
tcgtggtggt ggtgtctggg 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 11
aggagtgtct cttccactgc 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 12
cttgtatgag aagtggctgg 20

<210> 13

COPY

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 13
cccagacacc aacaccacga t

21

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 14
gtctgtcttt ggaggatggg

20

<210> 15
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 15
agaggtggac aaagtacttg g

21

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 16
ggaagccagc atttccaggg

20

<210> 17
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 17
cctacacttc gctggtcctg ggcgtcctgg tctgc

35

<210> 18
<211> 22

A rectangular stamp with the word "COPY" in a bold, sans-serif font. To the left of the word is a small square containing the letter "C".

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 18

caagtacttt gtccacctct cc



UNITED STATES PATENT AND TRADEMARK OFFICE

COPY

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/573,804	Martine Aiach	P08898US00BAS

881
 STITES & HARBISON PLLC
 1199 NORTH FAIRFAX STREET
 SUITE 900
 ALEXANDRIA, VA 22314

RECEIVED

FEB 22 2007

STITES & HARBISON PLLC

INTERNATIONAL APPLICATION NO.	
PCT/IB04/03146	
I.A. FILING DATE	PRIORITY DATE
09/28/2004	09/29/2003

CONFIRMATION NO. 9377

371 FORMALITIES LETTER



OC000000022559297

Date Mailed: 02/21/2007

4-21-2007

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 03/28/2006
- Copy of the International Search Report filed on 03/28/2006
- U.S. Basic National Fees filed on 03/28/2006
- Priority Documents filed on 03/28/2006

COPY

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Additional claim fees of **\$360** as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$490** for a Large Entity:

- **\$130** Surcharge.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

- Total additional claim fee(s) for this application is \$ 360

COPY

- \$360 for multiple dependent claim surcharge.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

COPY

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.

<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

ANITA D JOHNSON

Telephone: (703) 308-9140 EXT 226

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/573,804	PCT/IB04/03146	P08898US00BAS

FORM PCT/DO/EO/905 (371 Formalities Notice)

COPY

COPY

COPY

Customized PTO/SB/01 (08-03)

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)	Docket No.	
	1 st Inventor	
	COMPLETE IF KNOWN	
Declaration Submitted with Initial Filing	Appl. No.	
Declaration Submitted after Initial Filing	Filing Date	

I hereby declare that:

Each inventor's residence, mailing address and citizenship are as stated below next to their name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Identification of polymorphisms in the EPCR gene associated with thrombotic risk.

the specification of which:

_____ is attached hereto

OR

_____ was filed on September 28, 2004 as PCT International Application No. PCT/IB2004/003146
and (if applicable) was amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim FOREIGN PRIORITY benefits under 35 USC 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's certificate(s), or 365(a) of any PCT international application which designated at least one country other than the US, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed. (____ Additional applications listed on supplemental sheet provided herewith)

Prior Foreign Appl. No.	Country	Filing Date (Day/Month/Year)	Priority Not Claimed
03292392.2	EUROPE	29.09.2003	Yes

Power Of Attorney & Correspondence Address Indication



I hereby appoint the practitioners (of Stites & Harbison PLLC) associated with

CUSTOMER NUMBER 00881

as my/our attorneys or agents to prosecute the application identified above, and to transact all business in the US Patent and Trademark Office connected therewith.

Please direct all correspondence to the noted Customer Number.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. (____ Additional inventors named on supplemental sheet provided herewith)

SOLE OR FIRST INVENTOR		Citizenship	French
Given Name (First and Middle (if any))	Martine	Family Name or Surname	AIACH
Full Mailing Address	70 rue Brancas - 92310 SEVRES - FRANCE		
Residence - City, State/Country (if different from mailing address)	"same as above"		
SIGN AND DATE HERE	Inventor's Signature 	Date	April 3, 2006
SECOND JOINT INVENTOR (if any)		Citizenship	French
Given Name (First and Middle (if any))	Sophie	Family Name or Surname	GANDRILLE
Full Mailing Address	197 rue de Lourmel - 75015 PARIS - FRANCE		
Residence - City, State/Country (if different from mailing address)	"same as above"		
SIGN AND DATE HERE	Inventor's Signature 	Date	April 3, 2006
THIRD JOINT INVENTOR (if any)		Citizenship	French
Given Name (First and Middle (if any))	Béatrice	Family Name or Surname	SAPOSNIK
Full Mailing Address	85 avenue du Général Michel Bizot - 75012 PARIS - FRANCE		
Residence - City, State/Country (if different from mailing address)	"same as above"		
SIGN AND DATE HERE	Inventor's Signature 	Date	April 5, 2006

Stites & Harbison PLLC • 1199 North Fairfax Street • Suite 900 • Alexandria Virginia 22314
TEL (703) 739-4900 • FAX (703)-739-9577

COPY

Customized PTO/SB/01 (08-03)

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) SUPPLEMENTAL SHEET (use as required)	Docket No.	
	1 st Inventor	
	COMPLETE IF KNOWN	
	Serial No.	
	Filing Date	

Additional Prior Foreign Application(s):			
Prior Foreign Appl. No.	Country	Day/Month/Year Filed	Priority Not Claimed

Name Of Additional Joint Inventor, if any		Citizenship	French
Given Name (First and Middle [if any])	Pascale	Family Name or Surname	GAUSSEM
Full Mailing Address	8 rue du Général Castelnau – 94240 L'HAY LES ROSES - FRANCE		
Residence - City, State/Country (if different from mailing address)	"Same as above"		
SIGN AND DATE HERE	Inventor's Signature <i>P. Gaussem</i>	Date	APRIL 5th, 2006

Name Of Additional Joint Inventor, if any		Citizenship	French
Given Name (First and Middle [if any])	Joseph	Family Name or Surname	EMMERICH
Full Mailing Address	112 rue Rambuteau – 75001 PARIS - FRANCE		
Residence - City, State/Country (if different from mailing address)	"Same as above"		
SIGN AND DATE HERE	Inventor's Signature <i>J. Emmerich</i>	Date	April 3, 2006

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle [if any])		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle [if any])		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle [if any])		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle [if any])		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

COPY

INFORMATION DISCLOSURE STATEMENT	Application #	10/573,804
	Confirmation #	9377
	Filing Date	03/28/06
	First Inventor	AIACH
	Art Unit	
	Examiner	
	Docket #	P08898US00/BAS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

S I R :

This IDS is submitted pursuant to 37 CFR. §1.97-1.98 and includes the following:

- ☒ A **listing** of the references on PTO-1449.
- ☒ A copy of all **non-US** references which are listed on the PTO-1449 (US refs not required).
- ☒ A copy of a corresponding foreign **Search Report** which explains the relevance of the references noted therein.
- ☐ A separate **explanation of relevance**.

Please note the following particulars concerning the filing of this IDS:

- ☒ 1. This IDS is filed at whichever is the latest of:
 - within three months of the filing date of a NATIONAL APPLICATION other than a CPA, or
 - within three months of the date of entry into the NATIONAL STAGE as set forth in 37 CFR. §1.491 in an international application, or
 - before the mailing date of a first Office Action on the merits or after filing of an RCE (*but if a first Office Action is mailed but not yet received and the date on the face of the attached foreign communication makes it evident that this IDS is submitted within three months from the mailing of the search report, then applicant is entitled to have this IDS considered under 2.B. below and such boxes should be considered as having been checked*).
 - ☐ 2. This IDS is filed **after a first Office Action**, but before a Final Action, Allowance, or any other action which closes prosecution, and:
 - ☐ A. Is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).
- or
- ☐ B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
 - ☐ C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.
 - ☐ D. An appropriate Statement is attached.

COPY

☐ 3. This IDS is filed **after** a final action or allowance, but on/before payment of the issue fee, and:

☐ A. is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).

and

☐ B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☐ C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.

☐ D. An appropriate Statement is attached.

☐ 4. This IDS does not comply with 37 CFR 1.97-1.98, and is being filed **for placement in the file** pursuant to 37 CFR. §1.97(i). .


☒ 5. It will also be appreciated that:

- a. It is believed that this IDS complies fully with 37 CFR 1.56 and 1.97-98 and with MPEP § 609; but if for some reason it does not and will not be entered, the examiner is requested to telephone the undersigned so that any deficiency can be timely remedied.
- b. Some of the documents may have markings thereon, but no significance should be attached to those markings.
- c. These documents are not necessarily analogous art.
- d. Where an English language translation of an abstract is provided from a public source, applicant cannot vouch for the accuracy of that translation.

☒ 6. If no payment is enclosed and a fee is due in connection with this communication or if the payment enclosed is insufficient, the Director is authorized to charge any fee or additional fee due with this communication to Deposit Account No. 12-0555.

Respectfully submitted,

Date: May 21, 2007



By: B. Aaron Schulman

Registration No.: 31,877

STITES & HARBISON PLLC ♦ 1199 North Fairfax St. ♦ Suite 900 ♦ Alexandria, VA 22314

TEL: 703-739-4900 ♦ FAX: 703-739-9577 ♦ CUSTOMER NO. 00881

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application #	10/573,804		
		Confirmation #	9377		
		Filing Date	03/28/06		
		First Inventor	AIACH		
		Art Unit			
		Examiner			
Sheet <u>1</u> of <u>1</u>		Docket #	P08898US00/BAS		
U.S. PATENT DOCUMENTS					
Exam. Initial*	Document No. Number - Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.	
	US-				
FOREIGN PATENT DOCUMENTS					
Exam. Initial*	Country-Number-Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.	Translation
NON PATENT LITERATURE DOCUMENTS					
Exam. Initial*	Include NAME of the author (in CAPS), Title of Article/Item, Date, Page(s), Volume-Issue No., Publisher, City and/or Country where published				Translation
	HAYASHI et al, "Organization and chromosomal localization of the human endothelial protein C receptor gene." Oct. 1, 1999, pp. 367-373, vol. 238, no. 2				
	ESPANA et al, "A new polymorphism in the 3' UTR region of the endothelial protein C receptor associated with increased levels of circulating activated protein C and decreased risk of venous thrombosis", 2001, pg. 0C885, Thromb. Haemost.				
	MEDINA et al, "the 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene is associated with levels of soluble plasma EPCR", July 2003, p. P0026, vol. 1				
	DATABASE SNP "Online! NCBI: database accession no. RS2069945				
	DATABASE SNP "Online! NCBI: database accession no. RS867186				
	DATABASE SNP "Online! NCBI: database accession no. RS2069944				
	DATABASE SNP "Online! NCBI: database accession no. RS2069948				
	DATABASE SNP "Online! NCBI: database accession no. RS945960				
	DATABASE SNP "Online! NCBI: database accession no. RS2069950				
	DATABASE SNP "Online! NCBI: database accession no. RS9574				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* Examiner: Initial if considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PTO STAMPED RECEIPT	Application #	10/573,804
	Confirmation #	9377
	Filing Date	03/28/06
	First Inventor	AIACH
	Art Unit	
	Examiner	
	Docket #	P08898US00/BAS

PAPERS SUBMITTED

COPY

- | | |
|---|---|
| <input type="checkbox"/> Transmittal Form
<input checked="" type="checkbox"/> Amendment
<input checked="" type="checkbox"/> with Attachments
<input type="checkbox"/> Amendment/Response After Final
<input type="checkbox"/> with Attachments
<input checked="" type="checkbox"/> Petition for Extension of Time
<input checked="" type="checkbox"/> Response to Missing Parts
<input checked="" type="checkbox"/> Declaration
<input type="checkbox"/> Translation of Application
<input type="checkbox"/> Assignment
<input type="checkbox"/> Priority Document
<input checked="" type="checkbox"/> Fee of \$250 (CREDIT CARD - PTO-2038)
<input checked="" type="checkbox"/> Copy of Notice
<input type="checkbox"/> | <input checked="" type="checkbox"/> IDS: Including
<input checked="" type="checkbox"/> List of References
<input checked="" type="checkbox"/> Search Report
10 Refs. Transmitted
<input type="checkbox"/> Statement of Relevance
<input type="checkbox"/> Issue Fee Transmittal
<input type="checkbox"/> Publication Fee Transmittal
<input type="checkbox"/> Letter to Draftsman
sheets of formal drawings
(figs.)
<input type="checkbox"/> Notice of Appeal
<input type="checkbox"/> Appeal Brief
<input type="checkbox"/>
<input type="checkbox"/> |
|---|---|

PTO Receipt Stamp →

